For children with Ewing sarcoma, an aggressive bone cancer, a combination of two different classes of drugs may work synergistically to turn off the drivers fueling this disease, according to a new study. The combination appears to be more powerful than relying on either treatment alone (Clin Cancer Res 2019;25[14]:4552-4566).
The study is the latest in a series of investigations performed by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and their